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ABSTRACT
The cardiac muscle ryanodine receptor-Ca2+ release channel (RyR2)
constitutes the sarcoplasmic reticulum (SR) Ca2+ efflux mechanism
that initiates myocyte contraction, while cardiac myosin-binding
protein-C (cMyBP-C; also known as MYBPC3) mediates regulation
of acto-myosin cross-bridge cycling. In this paper, we provide the first
evidence for the presence of direct interaction between these two
proteins, forming a RyR2–cMyBP-C complex. The C-terminus of
cMyBP-C binds with the RyR2 N-terminus in mammalian cells and
the interaction is not mediated by a fibronectin-like domain. Notably,
we detected complex formation between both recombinant
cMyBP-C and RyR2, as well as between the native proteins in
cardiac tissue. Cellular Ca2+ dynamics in HEK293 cells is altered
upon co-expression of cMyBP-C and RyR2, with lowered frequency
of RyR2-mediated spontaneous Ca2+ oscillations, suggesting that
cMyBP-C exerts a potential inhibitory effect on RyR2-dependent
Ca2+ release. Discovery of a functional RyR2 association with
cMyBP-C provides direct evidence for a putative mechanistic link
between cytosolic soluble cMyBP-C and SR-mediated Ca2+ release,
via RyR2. Importantly, this interaction may have clinical relevance to
the observed cMyBP-C and RyR2 dysfunction in cardiac pathologies,
such as hypertrophic cardiomyopathy.
KEYWORDS: Ca2+ signalling, Myosin-binding protein C, Sarcomere,
Ryanodine receptor, Sarcoplasmic reticulum, Excitation–
contraction coupling
INTRODUCTION
Cardiac muscle excitation–contraction coupling, where the
electrical depolarisation stimulus of cardiomyocytes plasma
membrane triggers mechanical contraction of the heart, is
mediated by Ca2+-induced Ca2+-release, where a small influx of
Ca2+ into the cytoplasm results in release of Ca2+ from SR. When
the heart is in the diastolic (relaxation) phase, intracellular Ca2+ is
sequestered into the sarcoplasmic reticulum (SR), the major internal
Ca2+ store of the cardiomyocyte. During systole (the contraction
phase), plasma membrane electrical excitation causes Ca2+ influx
through coordinated opening of voltage-gated Ca2+ channels,
leading to a global efflux of Ca2+ from the SR via the SR-located
Ca2+ release channel-ryanodine receptor 2 complex (RyR2), which
in turn induces sarcomere shortening (Bers, 2002). Physiological
regulation of muscle contraction involves the control of acto-myosin
cross-bridge cycling, which is initiated by Ca2+ binding to troponin,
thus allowing the myosin thick-filament protein to interact with
actin, the thin-filament protein. The force and frequency of muscle
contraction is influenced by numerous factors including sarcomere
Ca2+ responsiveness, phosphorylation and various modulatory
proteins; among the latter is myosin-binding protein C (MyBP-C),
an important protein that plays a vital modulatory role (Clark et al.,
2002; Moss et al., 2015).
The three mammalian RyR protein isoforms (skeletal RyR1,
cardiac RyR2 and RyR3, which is expressed in various tissues)
share ∼65% sequence identity, with the concensus RyR oligomeric
structure composed of four identical subunits surrounding a
centrally located Ca2+ ion channel pore entailing the C-terminal
transmembrane domains of each protomer. In contrast, the much
larger cytoplasmic N-terminal assembly serves as a binding scaffold
for myriad accessory proteins, ions and other regulatory molecules
(Lanner et al., 2010). Modulation of RyR channel opening and
closing by stimulatory/inhibitory cytoplasmic signals is mediated
by long-range conformational changes involving the interplay
between N- and C-terminal domains within a single RyR subunit, as
well as between neighbouring subunits of the RyR tetramer (Seidel
et al., 2015a). Given the essential role of RyR in enabling SR Ca2+
release, it is unsurprising that functional alterations of RyRs are
associated with human disease (Lanner et al., 2010). Thus, RyR1
mutations are linked to skeletal muscle disorders including
malignant hyperthermia and central core disease, while RyR2
mutations have a direct causative role in the heart rhythm disorders
catecholaminergic polymorphic ventricular tachycardia (CPVT)
and arrhythmogenic right ventricular dysplasia (ARVD), and
discrete RyR2 mutations have also been recently implicated in
dilated cardiomyopathy (DCM) (Haas et al., 2014).
MyBP-C is an immunoglobulin (Ig) protein superfamily member
and exists in three isoforms: cardiac [cMyBP-C, which is exclusively
heart expressed (also known as MYBPC3)], and fast- and slow-
skeletal muscle types (also known as MYBPC2 and MYBPC1,
respectively) with an overall peptide sequence identity of ∼55%. All
three isoforms share common architectural features, comprising ten
globular domains designated C1–C10, seven of which are Ig-like
domains with the remaining three categorised as fibronectin-like
(Fn) type-3 domains. Notably, cMyBP-C contains an additional IgReceived 31 August 2017; Accepted 31 May 2018
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domain (C0) at the extreme N-terminus, a phosphorylation motif in
the M domain and an insertion within C5 (Moss et al., 2015;
Sadayappan and de Tombe, 2012; Sequeira et al., 2014). The
C-terminal domains are responsible for anchoring cMyBP-C to the
thick filament, while the N-terminus is thought to be involved in the
interaction with both myosin and actin (Moss et al., 2015;
Sadayappan and de Tombe, 2012; Sequeira et al., 2014).
Extensive cMyBP-C phosphorylation contributes to myosin head
alignment and extension towards the thin filaments, thus producing
strong actin–myosin interactions and enhanced contractile output
(Moss et al., 2015; Sadayappan and de Tombe, 2012; Sequeira et al.,
2014). Abnormalities in cMyBP-C are also associated with cardiac
disease pathogenesis. Dephosphorylation of cMyBP-C enhances its
dissociation from the sarcomere into the bulk cytoplasm (Govindan
et al., 2012), a cMyBP-C feature that is observed in animal models of
heart failure and pathologic hypertrophy (Sequeira et al., 2014).
Moreover, dominant mutations in slowMyBP-C have been linked to
the development of distal arthrogryposis (Geist and Kontrogianni-
Konstantopoulos, 2016), while cMyBP-C mutations have been
reported in hypertrophic cardiomyopathy (HCM), DCM and left
ventricular non-compaction (Carrier et al., 2015).
Impaired muscle relaxation and the alteration of subcellular Ca2+
signalling are common features in several animal models with
mutant cMyBP-C (Brickson et al., 2007; Pohlmann et al., 2007;
Song et al., 2003), pointing to a role for cMyBP-C as a multifaceted
signalling node in myocyte function that contributes to the
assembly, stabilisation and regulation of sarcomere shortening, as
well as to the critical modulation of Ca2+ homeostasis. Here, we
present several lines of evidence that suggests cMyBP-C influences
cardiomyocyte intracellular Ca2+ signalling via a novel
stoichiometric interaction with RyR2 Ca2+ release channels.
RESULTS
Identification of cMyBP-C as a novel RyR2-binding protein
To identify novel RyR2-binding proteins, we employed the yeast
two-hybrid (Y2H) system using an RyR2 N-terminal fragment
(residues 1–906, BT4L; RyR2NT) as the ‘bait’ to screen a human
heart cDNA library. Several positive clones were found and,
through nucleotide sequence analysis, were shown to encode the
C-terminus (residues 817–1274) of cMyBP-C (cMyBP-CCT).
When the isolated cMyBP-CCT clone was screened against a
series of overlapping fragments covering the entire length of RyR2,
a positive interaction was detected only for RyR2NT (Table 1),
demonstrating the RyR2 N-terminal (residues 1–906) domain-
specificity of cMyBP-CCT binding.
To reinforce our Y2H observations, putative binding of RyR2
to cMyBP-C was assessed by co-immunoprecipitation (co-IP)
following co-expression of distinct fusion constructs in mammalian
HEK293 cells, an immortalised cell lineage devoid of RyR2 and
cMyBP-C. Thus, HA-tagged cMyBP-CCT was immunoprecipitated
using anti-HA antibody (AbHA) and verified by immunoblotting
(Fig. 1A, bottom panel), while the presence of co-precipitated
cMyc-tagged RyR2NT was analysed by immunoblotting with anti-
Myc antibody (AbcMyc). The co-IP revealed that RyR2NT was
recovered in the AbHA immunoprecipitate but not in the rabbit IgG
control (Fig. 1A), suggesting that there is an interaction between the
recombinant proteins RyR2NT and cMyBP-CCT. Consistent with the
Y2H data (Table 1), parallel co-IP experiments revealed no
interaction of cMyBP-C with BT7 (Fig. 1A), a RyR2 central region
construct (residues 3071–3940) of similar size to BT4L. RyR2NTwas
also tested for an interaction either with full-length cMyBP-C
(cMyBP-CFL) or a large N-terminal fragment comprising domains
C0–C6 (NT, residues 1–865; cMyBP-CNT). Distinctive RyR2NT co-
precipitation was observed when co-expressed with cMyBP-CFL, but
was negligible for cMyBP-CNT (Fig. 1B,C). Densitometric analysis
indicates equivalent specific binding of RyR2NT with cMyBP-CFL
and cMyBP-CCT (Fig. 1D). In contrast, RyR2NT binding to
cMyBP-CNT, as well as BT7 binding for any cMyBP-C construct,
was minimal (Fig. 1D). These results indicate that RyR2 forms
complexes with cMyBP-C in vitro via an interaction between the
cMyBP-C C-terminus domain and the RyR2 N-terminus.
Given the high levels of sequence conservation across all three
isoforms of MyBP-C C-termini (∼70%), as well as for the N-
termini of all three RyR isoforms (>80%), the RyR1 and RyR3 N-
terminal fragments [BT4LR1, amino acids 1–915 (RyR1NT) and
BT4LR3, amino acids 1–911 (RyR3NT)] were also tested for
cMyBP-CCT binding in co-IP assays. Interaction of cMyBP-CCT
with both RyR1NT and RyR3NT was observed that was comparable
to that with RyR2NT (Fig. S2), suggesting that RyR–MyBP-C
association may occur in both cardiac and skeletal muscle.
Fibronectin-like type 3 domains mediate a robust RyR2–
cMyBP-C interaction
To determine the RyR2-binding site within cMyBP-CCT, which
comprises part of C6 and the C7–C10 domains (Fig. 2A), ten
overlapping cMyBP-CCT subfragments that had boundaries within
linker sequences between discrete structural domains, to facilitate
correct protein folding, were generated (Fig. 2A). Since the cMyBP-
CCT isolated in the Y2H screen contained only part of domain C6,
cMyBP-C constructs encoding the whole C6 domain (fC6) were
also prepared. Thus, co-IP assays (n≥5) with HEK293 cell lysates
co-expressing HA-tagged cMyBP-C constructs and RyR2NT
(Fig. 2B) were undertaken. Both the overlapping triple-domain
constructs, C6–C8 and C8–C10, displayed interaction with RyR2NT,
with a ∼3-fold stronger signal for C6–C8 versus C8–C10. Further
double-domain constructs C6–C7 and fC6–C7, C8–C9 and C9–C10
also exhibited RyR2NT binding, providing the apparent rank order;
C6–C8≈C6–C7>C8–C10≈C9–C10>>C8–C9. These results suggest
that there is an Fn domain requirement for the cMyBP–RyR2NT
interaction, in particular for C7 and then for C9, which share 36%
sequence identity. Domain C6, which appears to be dispensable,
since cMyBP-CNT exhibited minimal RyR2NT binding, has lower
sequence identity with C7 and C9 (22% and 24%, respectively).
Notably, individual domains C7 and C9 (as well as fC6, C8)
Table 1. Y2H β-galactosidase assay for cMyBP-C interaction with RyR2 constructs
BT4L
(1–906)
BT3
(677–
1621)
BT5
(1563–
2507)
BT6
(2346–
3131)
BT7
(3071–
3940)
BT71
(3788–
4204)
BT1A2
(3995–
4499)
BT1B
(4596–
4715)
BT1B2
(4596–
4765)
BT8
(4867–
4967)
AD/cMyBP-C
(817–1274)
+++ – – – – – – – – –
Results from the Y2H β-galactosidase assay for cMyBP-C (fusion AD/cMYBP-C) interaction with overlapping RyR2 fusion constructs (denoted BT). +++, strong
interaction; –, no interaction.
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displayed negligible RyR2NT binding, suggesting that two domains
are minimally required either to comprise the appropriate
conformation or to jointly contribute to the RyR2-binding interface.
Similarly, to further map the cMyBP-C binding site within the
RyR2 N-terminus, a series of eight overlapping cMyc-tagged
RyR2NT subfragments (Fig. 2C) were co-expressed together with
cMyBP-CCT in HEK293 cells for co-IP assays. Quantitative (n≥5)
densitometry and statistical analysis indicates that RyR2NT
subfragments BT4 (residues 1–759), BT4D (residues 161–759),
BT4DL (residues 161–906) and BT4EL (residues 565–906) retain
significant cMyBP-C binding (compared to their respective non-
specific binding, P<0.05), although binding was reduced relative to
RyR2NT (Fig. 2D). These results suggest multiple determinants
within the RyR2 N-terminus are necessary for robust interaction
with cMyBP-C.
Native porcine cardiac and recombinant human RyR2–
cMyBP-C association
To further confirm the cMyBP-CCT interaction with RyR2NT that
was seen in the heterologous expression system (yeast), we sought
to identify the putative RyR2–cMyBP-C association in native
mammalian tissue. Initially, we investigated cMyBP-C expression
in the SR compartment, using porcine cardiac SR and antibodies
raised against either the cMyBP-C N-terminus or C-terminus (AbC-NT
and AbC-CT, respectively; Fig. S3). Following subcellular
fractionation, a proportion of the soluble cMyBP-C was detected
in the cytosol. Importantly, substantial amounts of cMyBP-C
co-migrated with the SR fraction suggesting association with an
SR-resident moiet(ies), potentially RyR2. To address such a
possibility, we performed RyR2 co-IP experiments using
solubilised pig cardiac tissue (with RyR2-specific Ab1093) and
co-precipitated cMyBP-C was monitored (using AbC-CT;
Fig. 3A,B). We determined that cMyBP-C was readily detected
upon RyR2 immuno-isolation, with statistically significant
specific binding between the native proteins (P<0.05).
Parallel experiments using HEK293 cells co-expressing both the
human proteins further demonstrated significant (P<0.05) specific
interaction between the recombinant human RyR2 and cMyBP-C
(Fig. 3C,D). Moreover, the co-immunolocalisation observed for
recombinant human RyR2 and cMyBP-C is consistent with
potential subcellular interaction between these proteins (Fig. 4A).
The proportion of RyR2-positive voxels that directly colocalised
with cMyBP-C was 71.2±4.1%, a significantly greater value than
for non-specific colocalisation obtained via geometric rotation of
the cMyBP-C image through 90° (38.6±6.7%, mean±s.e.m.,
P<0.05) (Fig. 4B; Fig. S4). The extent of colocalisation between
RyR2 and cMyBP-C was independent of the immunofluorescence
signal intensity corresponding to RyR2 expression levels (Fig. S4).
cMyBP-C modulates RyR2-mediated cellular Ca2+ dynamics
To ascertain whether cMyBP-C expression influences RyR2-
mediated intracellular Ca2+ handling, spontaneous Ca2+ release
events in HEK293 cells were monitored through confocal imaging.
N-terminal tagging of cMyBP-C with mCherry (mC–cMyBP-C),
Fig. 1. Interaction between the cMyBP-C
C-terminus and RyR2 N-terminus. Co-IP assays
from HEK293 cells co-expressing BT4L (cMyc-
tagged RyR2 residues 1–906) or BT7 (cMyc-tagged
RyR2 residues 3071–3940) together with HA-
tagged cMyBP-C CT (residues 817–1274) (A), FL
(full-length) (B), or NT (residues 1–866) (C).
HA-cMyBP-C constructs were immunoprecipitated
with AbHA from solubilised cell lysates and the
presence of co-precipitated BT4L/BT7 was analysed
by western blotting using AbcMyc (top). To detect
immuno-isolated HA–cMyBP-C, 1/10th of the IP
samples was analysed by western blotting using
AbHA (bottom). Non-immune rabbit IgG served as
negative control (non-specific binding). An aliquot of
HEK293 cell lysate corresponding to 0.5% of the
amount processed in the co-IP assay was included
in the gels to assess protein expression. (D) Data
summary (n≥5) following densitometry analysis and
normalisation to the values in the lysate for each
respective construct (taken as 100%); data are given
as mean±s.e.m. *P<0.05 (paired two-tailed
Student’s t-test).
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which is spectrally distinct from fluo-3 Ca2+-reporting dye, enabled
visualisation of cells expressing mC–cMyBP-C. Parallel
experiments were completed with two separate cell populations
expressing: (1) RyR2 and mC-cMyBP-C, and (2) RyR2 and
mCherry (Fig. 5A). The Ca2+ transient amplitude (Fig. 5B), Ca2+
transient duration (Fig. 5C), rate of Ca2+ release (Fig. 5D), Ca2+
decay rate (Fig. 5E) and endoplasmic reticulum (ER) Ca2+ store
content (Fig. 5G) were unaffected by the presence of mC–cMyBP-C
or mCherry. The specific distinction between cells expressing RyR2
plus mC-cMyBP-C, relative to RyR2 plus mCherry, was a
substantial and statistically significant decrease in the number of
spontaneous Ca2+ oscillations (P<0.05, Fig. 5F). This reduced
propensity for spontaneous RyR2-mediated Ca2+ release in the
specific presence of mC–cMyBP-C would be consistent with an
inhibitory role for cMyBP-C on RyR2 channel function.
DISCUSSION
Excitation–contraction coupling is considered to be a unidirectional
process where the rise in intracellular Ca2+ concentration triggered
by an action potential induces sarcomere contraction. Given that
dephosphorylated cMyBP-C is released from the sarcomere in
pathological conditions (Baker et al., 2015; Decker et al., 2012;
Govindan et al., 2012; Kulikovskaya et al., 2007; Kuster et al.,
2014), the structural and functional interaction between the SR-
resident RyR2 and sarcomere-released, soluble cMyBP-C,
described in the present study, may therefore constitute an
important, and previously unrecognised, feedback regulatory
mechanism (Fig. 6). Our initial observation of an interaction
between the RyR2 N-terminus and the cMyBP-C C-terminus
provided from an unbiased transcriptome-wide screen, was further
verified by biochemical assays (Fig. 1). Parallel experiments with
the corresponding N-terminal fragment from skeletal muscle
isoform RyR1 indicated a robust interaction with cMyBP-C
(Fig. S2), suggesting that MyBP-C binding might be relevant not
only in cardiac, but also in skeletal muscle and smooth muscle.
Importantly, porcine cMyBP-C was found to associate with the
cardiac SR subcellular endomembranous compartment (Fig. S3)
and to co-immunoprecipitate with native porcine RyR2 (Fig. 3).
Moreover, human cMyBP-C colocalised with RyR2 in HEK293
cells (Fig. 4), co-immunoprecipitated with human RyR2 (Fig. 3)
and modulated spontaneous RyR2 Ca2+ release (Fig. 5). That
cMyBP-C dephosphorylation is required for sarcomere dissociation
(Govindan et al., 2012) suggests that dephosphorylated cMyBP-C is
the form that interacts with RyR2. As the functional phosphorylation
sites of cMyBP-C are at the N-terminus (Moss et al., 2015), while the
RyR2 interaction site occurs via the C-terminus, it appears unlikely
that cMyBP-C phosphorylation would have a direct impact on RyR2
association. However, the precise role of cMyBP-C phosphorylation
status on specific binding with RyR2 and its pathophysiological
significance remains to be resolved.
To our knowledge, these observations constitute the first report
that suggests a direct role may exist for cMyBP-C in the regulation
of RyR2-mediated Ca2+ homeostasis. Our data are consistent with
previous indirect evidence from transgenic mouse models showing
that an altered cMyBP-C protein is linked to the prolongation of Ca2+
release events (Brickson et al., 2007; Pohlmann et al., 2007; Song
Fig. 2. Mapping of binding sites in RyR2 and cMyBP-C. Schematic diagram of (HA-tagged) constructs covering the cMyBP-C C-terminus (A) and RyR2 N-
terminus (Myc-tagged) subfragments (denoted BT) (C). Co-IP assays from HEK293 cells co-expressing BT4L with HA–cMyBP-C constructs (B), or cells co-
expressing BT constructs with HA–cMyBP-C/CT (D). Data summary (n=numbers for each data set are: left, CT, 9; C6–C8, 3; C8–C10, 8; fC6–C7, 3; C6–C7, 4;
C8–C9, 6; C9–C10, 4; fC6, 8; C7, 7; C8, 8; C9, 7; right, BT4L, 9; BT4, 4; BT4A, 7; BT4B, 7; 5, BT4C; 6, BT4D; BT4BL, 7, BT4DL, 4; BT4EL, 7) following
quantitative densitometry analysis and normalisation to each construct’s respective lysate (taken as 100%); data are given as mean±s.e.m. *P<0.05 (paired two-
tailed Student’s t-test).
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et al., 2003). While this effect of an altered cMyBP-C could be
explained by increased myofilament Ca2+ sensitivity (Huke and
Knollmann, 2010), a plausible alternative or additional mechanism
may involve a role for cMyBP-C modulation of a crucial Ca2+
signalling component.
The rate of Ca2+ transient decay is governed by the multilateral
involvement of: (1) the SR/ER Ca2+/ATPase (SERCA) pumping
Ca2+ into the SR, (2) phospholamban inhibiting SERCA activity,
which could be relieved following phospholamban
phosphorylation, (3) the Na+/Ca2+ exchanger (NCX) extruding
Ca2+ out of the cell, and (4), the SR Ca2+ leak through the RyR2,
which could be substantial in pathological conditions (Bers, 2002;
Bers et al., 2003; George, 2008). The relative contribution of
SERCA is ∼92%, whereas that of NCX is ∼7% for diastolic Ca2+
removal in the mouse heart (Bers, 2002). In cMyBP-C knockout
mice, RyR2 expression and/or channel activity was not investigated
but the level of NCX activity was 34% lower (Pohlmann et al.,
2007), which could partly account for the prolonged Ca2+ transient
observed. However, the level of phosphorylated phospholamban
was 3-fold higher in knockout mouse hearts (with unchanged
SERCA and phospholamban protein levels) (Pohlmann et al.,
2007), and therefore a reduction in Ca2+ transient duration would be
predicted rather than an increase. Given the 13:1 SERCA (∼92%):
NCX (∼7%) contribution to diastolic Ca2+ removal, the prolonged
Ca2+ transient seen in cMyBP-C knockout mice appears highly
unlikely to be solely due to 34% lower NCX levels – a notable
alternative/additional contribution may be the involvement of SR
Ca2+ leak through the RyR2. In this scenario, it could be postulated
that cMyBP-C is normally required to suppress diastolic SR Ca2+
Fig. 3. Native pig and recombinant human RyR2–cMyBP-C interaction.
Co-IP assays from pig cardiac tissue (A) or HEK293 cells co-expressing full-
length human RyR2 with human cMyBP-C/FL (C). RyR2 was
immunoprecipitated with Ab1093 from solubilised pig cardiac (A) or HEK293 cell
lysate (C), and the presence of co-precipitated cMyBP-C was analysed by
western blotting using AbC-CT or AbHA, respectively (top). To detect immuno-
isolated RyR2, 1/10th of the IP samples was analysed by western blotting
using AbP12 (bottom). Non-immune rabbit IgG served as negative control (non-
specific binding). An aliquot of cell lysate corresponding to 0.5% of the amount
processed in the co-IP assay was included in the gels to assess protein
expression. (B,D) Data summary (n=5) following densitometry analysis and
normalisation to the lysate (taken as 100%); data are given as mean value
±s.e.m. *P<0.05 (paired two-tailed Student’s t-test).
Fig. 4. Subcellular colocalisation of RyR2 with cMyBP-C in HEK293 cells.
(A) Representative images of the intracellular distribution of heterologous
RyR2 (green) and cMyBP-C (red) in a single HEK293 cell. Composite images
were generated in which spatially colocalised voxels corresponding to RyR2
and cMyBP-C were overlaid (yellow). The corresponding bright-field image of
the cell is also given (BF). (B) The extent of RyR2 colocalisation with cMyBP-C
was quantified. Non-specific colocalisation was assessed following geometric
rotation of the cMyBP-C image through 90° (also see Fig. S4). The data on
RyR2–cMyBP-C colocalisation are plotted as mean±s.e.m. and are from
analysis of 192 cells from four separate experiments. The values resulting from
the rotation of cMyBP-C images through 90° are given asmean±s.e.m. and are
from the analysis of 10 randomly selected images. *P<0.05 (paired two-tailed
Student’s t-test).
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leak through its interaction with RyR2 (Fig. 6). The putative
suppression of RyR2 channel activity by cMyBP-C, interpreted
from electrically stimulated Ca2+ transients in cardiomyocytes, is
entirely consistent with our cMyBP-C co-expression results
showing a reduced propensity for RyR2-mediated spontaneous
Ca2+ transients in a mammalian cell line (Fig. 5), although Ca2+
release event duration was unaltered.
Formation of the RyR2–cMyBP-C complex in cardiomyocytes
will depend on the cMyBP-C subcellular distribution. As part of the
physiological sarcomeric protein turnover, cMyBP-C is known to
exist as two different forms in vivo, the predominant phosphorylated
form (associated with greater thick filament stability) and a second
dephosphorylated form (Moss et al., 2015; Sadayappan and de
Tombe, 2012). The latter is relatively sensitive to release from the
sarcomere, with low levels of full-length cMyBP-C reported in the
cytosol (Baker et al., 2015; Decker et al., 2012; Kuster et al., 2014),
which is in agreement with our own observations (Fig. S3). Notably,
an increased rate of cMyBP-C dephosphorylation, and its
subsequent dissociation from the sarcomere and further
degradation, has been reported in the heart of animal models and
patients with heart failure, myocardial infarction, ischaemia–
reperfusion injury and pathological hypertrophy (Baker et al.,
2015; Decker et al., 2012; Govindan et al., 2012; Kulikovskaya
et al., 2007; Kuster et al., 2014). Interestingly, high-resolution
imaging of cMyBP-C and RyR2 revealed that sarcomere-bound
cMyBP-C is the predominant form in healthy cardiomyocytes
(Previs et al., 2015), with significant release of cMyBP-C into the
cytosol after myocardial infarction/reperfusion (Govindan et al.,
2012) and in pathologic hypertrophy (Sequeira et al., 2014). Thus, it
is plausible that sarcomere-dissociated cMyBP-C may be available
for RyR2 interaction and modulation of SR Ca2+ release,
particularly in the above cardiopathologic conditions (Fig. 6).
The RyR2:cMyBP-C association could also be relevant in DCM
and HCM, cardiomyopathies often accompanied by an
arrhythmogenic phenotype (Maron et al., 2014; Spezzacatene
et al., 2015). RyR2mutations including those within the N-terminus
have recently been linked to DCM (Haas et al., 2014), whereas
mutations in cMyBP-C are very common in both HCM and DCM
pathology (Carrier et al., 2015), with some cMyBP-C mutations
reported to trigger arrhythmic events (Bahrudin et al., 2008; Berul
et al., 2001). A proportion of mutants encode for cMyBP-C
truncated protein(s) that lack the C-terminal C10 domain, a
structural element critical for association with the thick filament
(Flashman et al., 2007) but a domain entirely dispensable for RyR2
binding (Fig. 2). It should be noted though that the likely pathogenic
mechanism of such mutations is haploinsufficiency, since the
predicted cMyBP-C truncated polypeptides could not be detected in
human patient samples (Carrier et al., 2015; Sequeira et al., 2014).
Proteins with missense mutations (e.g. A31P and E258K) are likely
to be expressed and incorporated into the myofilaments (De Lange
et al., 2013; Harris et al., 2011), whereas a 25-nucleotide frameshift
deletion resulting in a novel sequence within the C10 domain
exhibits little incorporation into the C-zone of the sarcomere and
localises at the Z-line (Kuster et al., 2015) – a specific location
where the RyR2 is found. Interestingly, cMyBP-C mutations
resulting in truncation have been mostly associated with HCM,
whereas missense mutations are mostly linked with DCM
(Waldmuller et al., 2011). Two different mechanisms underlying
increased myofilament Ca2+ sensitivity and contractile dysfunction
have previously been proposed for cMyBP-C truncations and
missense mutations, respectively: (1) haploinsufficiency that might
also involve impairment of nonsense-mediated mRNA decay and/or
the ubiquitin-proteasome system, and (2) dominant-negative mutant
proteins acting as poison polypeptides (Carrier et al., 2015; Harris
Fig. 5. cMyBP-C alters RyR2-mediated Ca2+ handling in HEK293 cells. Single-cell Ca2+ imaging performed via confocal laser scanning microscopy to
monitor spontaneous intracellular Ca2+mobilisation. Representative traces (left, A) and summary of results (B–G) from cells expressing RyR2 plusmC–cMyBP-C
(n=70), or RyR2 plus mCherry (n=33). To estimate cell ER load, 10 mM caffeinewas added after 2 min 30 s and data were recorded for a further 30 s. Parameters
of Ca2+ release events analysed include amplitude (B), duration (C), rate of release (D), rate of decay (E), frequency (F) and Ca2+ store content (G). Data are
normalised for RyR2 alone and are presented asmean±s.e.m. *P<0.05 [one-way ANOVAwith Bonferroni’smultiple comparisons test (B–E) or Kruskal–Wallis test
with Dunn’s multiple comparisons test (F,G)].
6
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs210443. doi:10.1242/jcs.210443
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
et al., 2011; Sequeira et al., 2014). Our study raises the possibility
that perturbation of Ca2+ homeostasis due to altered RyR2–cMyBP-
C interactions may constitute an additional pathogenic mechanism
contributing to the development of DCM, HCM and/or
arrhythmogenicity. Future studies are required to unravel the
precise molecular mechanism(s) by which MyBP-Cs are involved
in, possibly dynamic, RyR isoform-specific regulation of SR Ca2+
release and to fully elucidate the role of RyR2–cMyBP-C
association in cardiac physiology and disease.
MATERIALS AND METHODS
Materials
Mammalian cell culture reagents and Fluo-3 AM were obtained from
Thermo Scientific, herring testes carrier DNA from Takara, protease
inhibitor cocktail (Complete™) from Roche, Protein-A–Sepharose from GE
Healthcare, electrophoresis equipment and reagents from Bio-Rad,
enhanced chemiluminescence detection kit from Thermo Scientific, DNA
restriction endonucleases from New England Biolabs and the Pfu DNA
polymerase from Promega; oligonucleotides and all other reagents were
from Sigma unless otherwise stated.
Antibodies
Primary antibodies used were: rabbit RyR2-specific Ab1093 raised against
residues 4454–4474 of human RyR2 [used in co-immunoprecipitation (co-
IP) at 2 µg and immunofluorescence (IF) at 1:100 dilution] as previously
described (Zissimopoulos et al., 2012, 2006), mouse RyR2 AbP12 raised
against residues 2846–2859 of human RyR2 [used in western blotting (WB)
at 1:500 dilution, see Fig. S1], sheep cMyBP-C-specific AbC-CT (AF7199,
R&D Systems) raised against mouse cMyBP-C residues 998–1100 (used in
WB at 1:200 dilution), mouse cMyBP-C-specific AbC-NT (E7, Santa Cruz
Biotechnology) raised against residues 1–120 of human cMyBP-C (used in
WB at 1:500 dilution and IF at 1:100 dilution), rabbit AbHA (Y-11, Santa
Cruz Biotechnology; used in co-IP at 2 μg per reaction), non-immune rabbit
Fig. 6. Working hypothesis for
retrograde regulation of SR Ca2+
release by the sarcomere. In the healthy
heart, an action potential triggers a
transient rise in the intracellular Ca2+
concentration, which in turn induces
sarcomere contraction. cMyBP-C is in its
phosphorylated form and predominantly
associated with myofilaments, where it
regulates acto-myosin cross-bridge
formation. In pathological conditions
associated with SR Ca2+ leak (Failing
heart) leading to intracellular Ca2+
overload, dephosphorylated cMyBP-C
translocates from the sarcomere to the SR,
where it suppresses Ca2+ leak through its
interaction with RyR2 (Retrograde
regulation) facilitating normal Ca2+
homeostasis and contraction. AP, action
potential; LTCC, L-type Ca2+ channel;
NCX: Na+/Ca2+ exchanger; PLN,
phospholamban; SERCA, SR/ER Ca2+
ATPase.
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IgG (Santa Cruz Biotechnology; used in co-IP at 2 μg), mouse AbHA
[16B12, Covance (BioLegend); used in WB at 1:1000 dilution], mouse
AbcMyc (9E10, Santa Cruz Biotechnology; used in WB at 1:500 dilution).
Secondary antibodies used were: goat anti-mouse IgG-horseradish
peroxidase conjugate (Santa Cruz Biotechnology; used in WB at 1:10,000
dilution), donkey anti-sheep IgG-horseradish peroxidase conjugate (R&D
Systems; used in WB at 1:5000 dilution), goat anti-rabbit IgG-Alexa Fluor
488 conjugate (A-11034, Thermo Scientific; used in IF at 1:500 dilution)
and goat anti-mouse IgG-Alexa Fluor 594 conjugate (A-11005, Thermo
Scientific; used in IF at 1:500 dilution).
Plasmid constructs
Plasmids encoding for RyR2 overlapping fragments (BT constructs) tagged
with the cMyc epitope at the N-terminus were as previously described
(Zissimopoulos et al., 2013). mCherry cDNA was obtained from Addgene
(plasmid #30125) and cloned into the mammalian expression vector pCR3
(Thermo Scientific). Human cMyBP-C cDNA was generated by PCR
amplification from a human heart cDNA library (Takara) and cloned into
pCR3 containing an N-terminal HA epitope tag or mCherry fusion protein.
Smaller HA-tagged cMyBP-C constructs were generated by PCR
amplification and cloned in the HA-modified pCR3 vector.
Oligonucleotide primers and restriction enzyme cloning sites used are
given in Table S1.
Mammalian cell culture
HEK293 cells (ATCC) were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 2 mM glutamine and 10% fetal bovine serum
(FBS) in a 37°C humidifying incubator with 5% CO2. For use in co-IP,
∼1.5×106 cells were seeded in one 100 mm Petri dish a day before
transfection in order to be 60–70% confluent the following day. Cells were
transfected with 24 μg of plasmid DNA using the calcium phosphate
precipitation method as described elsewhere (Stanczyk et al., 2016). For use
in IF, ∼0.25×106 cells were seeded onto poly-lysine-coated glass coverslips
(22 mm×22 mm), left to adhere overnight and transfected the following day
using TurboFect (Thermo Scientific) according to the manufacturer’s
instructions. For Ca2+ imaging, ∼1×105 cells were seeded on poly-lysine
coated glass bottom dishes (MatTek) and transfected using Effectene
(Qiagen) according to the manufacturer’s instructions.
Immunofluorescent detection of RyR2 and cMyBP-C
Transfected HEK293 cells were washed in phosphate-buffered saline (PBS)
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 pH 7.4)
and fixed with 4% paraformaldehyde for 10 min at room temperature. Fixed
cells were washed and re-hydrated with PBS for 1 h before permeabilisation
with 0.1% Triton X-100 for 30 min. Cells were washed with PBS, blocked
with 10% FBS for 1 h, and then incubated at room temperature for 2 h with
rabbit RyR2-specific Ab1093 and mouse cMyBP-C-specific AbC-NT
antibodies. Samples were then washed with PBS and incubated with
Alexa Fluor 488- and Alexa Fluor 594-conjugated goat anti-rabbit-IgG and
goat anti-mouse-IgG antibodies for fluorescent labelling of RyR2 and
cMyBP-C, respectively, at room temperature for 2 h in the dark. Following
final washing with PBS, the coverslips were washed in water, dried and
mounted onto glass slides using ProLong Gold Antifade reagent (Thermo
Scientific) and stored at 4°C until required. All antibodies were carefully
titrated to give comparable fluorescence signals under test. There was
negligible non-specific fluorescence in these cells as determined by using
the staining protocol as above but with one or both primary and secondary
antibodies omitted.
Image analysis and processing
Immunofluorescence signals corresponding to RyR2 and cMyBP-C were
visualised using a confocal microscope (SP5, Leica Microsystems) fitted
with a 63× oil immersion objective (NA 1.4). Signal intensity in the images
were adjusted to the full dynamic range using the operating software’s
‘glow-over’ function (LAS-AF, Leica Microsystems) and were collected
throughout the depth of each samples (z-stack 0.5 µm slices, 18.5±0.24
frames, and average depth of cell 8.6±1.2 µm). Individual z-plane images
were recombined into three-dimensional datasets using LAS-AF (Leica
Microsystems). Data were imported into Imaris (Bitplane, Andor
Technology) and the signal threshold for bona fide RyR2 and cMyBP-C-
positive voxels in each image was defined using the levels of non-specific
immunofluorescence established as above. Over the entire dataset (n=192
3D reconstructions from four separate transfections), RyR2- and cMyBP-C-
positive voxels were assigned to 2.8±0.1% and 7.8±0.3% (mean±s.e.m.) of
the total voxels, respectively. In each z-stack, the proportion of RyR2 voxels
that were spatially co-incident with cMyBP-C voxels was calculated using
Imaris software. Normally distributed data were subjected to statistical
testing using unpaired two-tailed Student’s t-test and non-normally
distributed data were tested using an unpaired Mann–Witney test. Linear
regression and the calculation of Pearson’s correlation coefficient (PCC)
was performed (Microsoft Excel, Office 2016). P<0.05 was taken as
significant.
Other methodologies
The Y2H system (Lam et al., 2013; Stanczyk et al., 2016; Zissimopoulos
et al., 2006), co-IP and WB (Stanczyk et al., 2016; Zissimopoulos et al.,
2012, 2013), cardiac SR preparation (Zissimopoulos et al., 2012) and single-
cell Ca2+ imaging (Handhle et al., 2016; Seidel et al., 2015b) were carried
out as previously described. Densitometry analysis was carried out using
GS700 densitometer (Bio-Rad) and Quantity-one (Bio-Rad) software.
Microsoft Excel was used to store and plot numerical data (expressed as
mean±s.e.m.), unless otherwise stated. Statistical analysis was performed
using GraphPad prism (GraphPad Software Inc). Data were first subjected to
the Brown–Forsythe test for the equality of group variances, and populations
with equal variance (no significantly different standard deviations, P<0.05)
were analysed using one-way ANOVA (with Bonferroni’s post-test). Where
data were non-normally distributed, the Kruskal–Wallis test (with Dunn’s
multiple comparisons test) was used.
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